Ethosuximide reverses paclitaxel- and vincristine-induced painful peripheral neuropathy

Akerley, 2000, Paclitaxel in advanced non-small cell lung cancer: an alternative high-dose weekly schedule., Chest, 117, 152S, 10.1378/chest.117.4_suppl_1.152S

Akerley, 1998, Phase I trial of weekly paclitaxel in advanced lung cancer., J Clin Oncol, 16, 153, 10.1200/JCO.1998.16.1.153

Aley, 1996, Vincristine hyperalgesia in the rat: a model of painful vincristine neuropathy in humans., Neuroscience, 73, 259, 10.1016/0306-4522(96)00020-6

Apfel, 1991, Nerve growth factor prevents toxic neuropathy in mice., Ann Neurol, 29, 87, 10.1002/ana.410290115

Authier, 1999, Pain related behaviour during vincristine-induced neuropathy in rats., NeuroReport, 10, 965, 10.1097/00001756-199904060-00013

Authier, 2000, Description of a short-term Ttaxol-induced nociceptive neuropathy in rats., Brain Res, 887, 239, 10.1016/S0006-8993(00)02910-3

Authier, 2003, An animal model of nociceptive peripheral neuropathy following repeated cisplatin injections., Exp Neurol, 182, 12, 10.1016/S0014-4886(03)00003-7

Bardos, 2003, BGP-15, a hydroximic acid derivative, protects against cisplatin- or taxol-induced peripheral neuropathy in rats., Toxicol Appl Pharmacol, 190, 9, 10.1016/S0041-008X(03)00155-8

van den Bent, 1997, Progression of paclitaxel-induced neuropathy following discontinuation of treatment., Muscle Nerve, 20, 750, 10.1002/(SICI)1097-4598(199706)20:6<750::AID-MUS15>3.0.CO;2-Y

Bian, 1995, Characterization of the antiallodynic efficacy of morphine in a model of neuropathic pain in rats., NeuroReport, 6, 1981, 10.1097/00001756-199510010-00007

Boyce, 1999, Selective NMDA NR2B antagonists induce antinociception without motor dysfunction: correlation with restricted localisation of NR2B subunit in dorsal horn., Neuropharmacology, 38, 611, 10.1016/S0028-3908(98)00218-4

Boyle, 1996, Glutamate ameliorates experimental vincristine neuropathy., J Pharmacol Exp Ther, 279, 410

Boyle, 1999, Amelioration of experimental cisplatin and paclitaxel neuropathy with glutamate., J Neurooncol, 41, 107, 10.1023/A:1006124917643

Boyle, 2001, The experimental neuroprotectant leukaemia inhibitory factor (LIF) does not compromise antitumour activity of paclitaxel, cisplatin and carboplatin., Cancer Chemother Pharmacol, 48, 429, 10.1007/s00280-001-0382-6

Campana, 1998, Prosaptide prevents paclitaxel neurotoxicity., Neurotoxicology, 19, 237

Caplow, 1994, How taxol modulates microtubule disassembly., J Biol Chem, 269, 23399, 10.1016/S0021-9258(17)31528-4

Cavaletti, 1995, Peripheral neurotoxicity of taxol in patients previously treated with cisplatin., Cancer, 75, 1141, 10.1002/1097-0142(19950301)75:5<1141::AID-CNCR2820750514>3.0.CO;2-U

Cavaletti, 1995, Experimental peripheral neuropathy induced in adult rats by repeated intraperitoneal administration of taxol., Exp Neurol, 133, 64, 10.1006/exnr.1995.1008

Cavaletti, 1997, Effect on the peripheral nervous system of the short-term intravenous administration of paclitaxel in the rat., Neurotoxicology, 18, 137

Cavaletti, 2002, Cisplatin-induced peripheral neurotoxicity in rats reduces the circulating levels of nerve growth factor., Neurosci Lett, 322, 103, 10.1016/S0304-3940(02)00091-5

Cella, 2003, Measuring the side effects of taxane therapy in oncology: the functional assesment of cancer therapy-taxane (FACT-taxane)., Cancer, 98, 822, 10.1002/cncr.11578

Chaudhry, 1994, Peripheral neuropathy from taxol and cisplatin combination chemotherapy: clinical and electrophysiological studies., Ann Neurol, 35, 304, 10.1002/ana.410350310

Chaudhry, 2003, Toxic neuropathy in patients with pre-existing neuropathy., Neurology, 60, 337, 10.1212/01.WNL.0000043691.53710.53

Chung, 1996, Effects of systemic morphine on neuropathic pain behaviors in an experimental rat model., Analgesia, 2, 151

Cliffer, 1998, Physiological characterization of taxol-induced large-fiber sensory neuropathy in the rat., Ann Neurol, 43, 46, 10.1002/ana.410430111

Connelly, 1996, Paclitaxel delivered as a 3-hr infusion with cisplatin in patients with gynecologic cancers: unexpected incidence of neurotoxicity., Gynecol Oncol, 62, 166, 10.1006/gyno.1996.0210

Coulter, 1989, Characterization of ethosuximide reduction of low-threshold calcium current in thalamic neurons., Ann Neurol, 25, 582, 10.1002/ana.410250610

De Santis, 2000, Patients treated with antitumor drugs displaying neurological deficits are characterized by a low circulating level of nerve growth factor., Clin Cancer Res, 6, 90

Dogrul, 2003, Reversal of experimental neuropathic pain by T-type calcium channel blockers., Pain, 105, 159, 10.1016/S0304-3959(03)00177-5

Forsyth, 1997, Prospective study of paclitaxel-induced peripheral neuropathy with quantitative sensory testing., J Neurooncol, 35, 47, 10.1023/A:1005805907311

van Gerven, 1994, Paclitaxel (taxol) induces cumulative mild neurotoxicity., Eur J Cancer, 30A, 1074, 10.1016/0959-8049(94)90459-6

Gogas, 1996, The impact of diabetes mellitus on the toxicity of therapy for advanced ovarian cancer., Gynecol Oncol, 61, 22, 10.1006/gyno.1996.0090

Gomora, 2001, Block of cloned human T-type calcium channels by succinimide antiepileptic drugs., Mol Pharmacol, 60, 1121, 10.1124/mol.60.5.1121

Gordon, 1997, Phase I dose escalation of paclitaxel in patients with advanced ovarian cancer receiving cisplatin: rapid development of neurotoxicity is dose-limiting., J Clin Oncol, 15, 1965, 10.1200/JCO.1997.15.5.1965

Haldar, 1997, Bcl2 is the guardian of microtubule integrity., Cancer Res, 57, 229

Hayakawa, 1994, Nerve growth factor prevents neurotoxic effects of cisplatin, vincristine and taxol, on adult rat sympathetic ganglion explants in vitro., Life Sci, 55, 519, 10.1016/0024-3205(94)00744-6

Heady, 2001, Molecular pharmacology of T-type Ca2 channels., Jpn J Pharmacol, 85, 339, 10.1254/jjp.85.339

Holmes, 1991, Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer., J Natl Cancer Inst, 83, 1797, 10.1093/jnci/83.24.1797-a

Iniguez, 1998, Reversible peripheral neuropathy induced by a single administration of high-dose paclitaxel., Neurology, 51, 868, 10.1212/WNL.51.3.868

Jordan, 1993, Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations., Proc Natl Acad Sci USA, 90, 9552, 10.1073/pnas.90.20.9552

Kilpatrick, 2001, Leukaemia inhibitory factor abrogates paclitaxel-induced axonal atrophy in the Wistar rat., Brain Res, 911, 163, 10.1016/S0006-8993(01)02627-0

Konings, 1994, Reversal by NGF of cytostatic drug-induced reduction of neurite outgrowth in rat dorsal root ganglia in vitro., Brain Res, 640, 195, 10.1016/0006-8993(94)91873-2

Kostyuk, 1992, Different action of ethosuximide on low- and high-threshold calcium currents in rat sensory neurons., Neuroscience, 51, 755, 10.1016/0306-4522(92)90515-4

Leresche, 1998, On the action of the anti-absence drug ethosuximide in the rat and cat thalamus., J Neurosci, 18, 4842, 10.1523/JNEUROSCI.18-13-04842.1998

Lipton, 1989, Taxol produces a predominantly sensory neuropathy., Neurology, 39, 368, 10.1212/WNL.39.3.368

Matthews, 2001, Effects of ethosuximide, a T-type Ca(2) channel blocker, on dorsal horn neuronal responses in rats., Eur J Pharmacol, 415, 141, 10.1016/S0014-2999(01)00812-3

Meijer, 1999, Cisplatin-induced DNA-platination in experimental dorsal root ganglia neuronopathy., Neurotoxicology, 20, 883

Nozaki-Taguchi, 2001, Vincristine-induced allodynia in the rat., Pain, 93, 69, 10.1016/S0304-3959(01)00294-9

Perez-Reyes, 2003, Molecular physiology of low-voltage-activated t-type calcium channels., Physiol Rev, 83, 117, 10.1152/physrev.00018.2002

Polomano, 2001, A painful peripheral neuropathy in the rat produced by the chemotherapeutic drug, paclitaxel., Pain, 94, 293, 10.1016/S0304-3959(01)00363-3

Postma, 1995, Paclitaxel-induced neuropathy., Ann Oncol, 6, 489, 10.1093/oxfordjournals.annonc.a059220

Quasthoff, 2002, Chemotherapy-induced peripheral neuropathy., J Neurol, 249, 9, 10.1007/PL00007853

Rowinsky, 1995, Paclitaxel (taxol)., N Engl J Med, 332, 1004, 10.1056/NEJM199504133321507

Rowinsky, 1993, Clinical toxicities encountered with paclitaxel (taxol)., Semin Oncol, 20, 1

Ryu, 1990, Low- and high-voltage-activated calcium currents in rat spinal dorsal horn neurons., J Neurophysiol, 63, 273, 10.1152/jn.1990.63.2.273

Schiff, 1979, Promotion of microtubule assembly in vitro by taxol., Nature, 277, 665, 10.1038/277665a0

Schmidt, 1995, Effect of nerve growth factor on peptide neurons in dorsal root ganglia after taxol or cisplatin treatment and in diabetic (dbdb) mice., Exp Neurol, 132, 16, 10.1016/0014-4886(95)90054-3

Scroggs, 1992, Calcium current variation between acutely isolated adult rat dorsal root ganglion neurons of different size., J Physiol, 445, 639, 10.1113/jphysiol.1992.sp018944

Seidman, 1997, Dose-dense therapy with paclitaxel via weekly 1-hour infusion: preliminary experience in the treatment of metastatic breast cancer., Semin Oncol, 24, S1772

Talley, 1999, Differential distribution of three members of a gene family encoding low voltage-activated (T-type) calcium channels., J Neurosci, 19, 1895, 10.1523/JNEUROSCI.19-06-01895.1999

Todorovic, 1998, Pharmacological properties of T-type Ca2 current in adult rat sensory neurons: effects of anticonvulsant and anesthetic agents., J Neurophysiol, 79, 240, 10.1152/jn.1998.79.1.240

Tredici, 1999, Effect of recombinant human nerve growth factor on cisplatin neurotoxicity in rats., Exp Neurol, 159, 551, 10.1006/exnr.1999.7174

Wani, 1971, Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia., J Am Chem Soc, 93, 2325, 10.1021/ja00738a045

Wasserheit, 1996, Phase II trial of paclitaxel and cisplatin in women with advanced breast cancer: an active regimen with limiting neurotoxicity., J Clin Oncol, 14, 1993, 10.1200/JCO.1996.14.7.1993

Weng, 2003, Changes in sensory processing in the spinal dorsal horn accompany vincristine-induced hyperalgesia and allodynia., Pain, 103, 131, 10.1016/S0304-3959(02)00445-1

Zimmermann, 1983, Ethical guidelines for investigations of experimental pain in conscious animals (editorial)., Pain, 16, 109, 10.1016/0304-3959(83)90201-4